BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
411.29
-5.25 (-1.26%)
Nov 16, 2026, 4:00 PM EST - Market closed
BeOne Medicines AG Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 42,829 | 36,945 | 27,587 | 15,528 | 9,766 | 7,472 |
Other Revenue | 408.99 | 426.46 | 224.05 | 1,907 | - | - |
| 43,238 | 37,371 | 27,811 | 17,435 | 9,766 | 7,472 | |
Revenue Growth | 22.14% | 34.37% | 59.51% | 78.53% | 30.69% | 270.56% |
Cost of Revenue | 4,407 | 4,676 | 4,336 | 2,694 | 1,976 | 1,048 |
Gross Profit | 38,831 | 32,695 | 23,475 | 14,741 | 7,790 | 6,425 |
Selling, General & Admin | 14,707 | 14,559 | 13,365 | 10,693 | 8,819 | 6,290 |
Research & Development | 15,576 | 15,009 | 14,257 | 12,612 | 11,315 | 9,270 |
Amortization of Goodwill & Intangibles | - | - | - | - | - | 4.76 |
Operating Expenses | 30,359 | 29,568 | 27,622 | 23,305 | 20,134 | 15,565 |
Operating Income | 8,472 | 3,127 | -4,147 | -8,564 | -12,344 | -9,140 |
Interest Expense | -390.62 | -407.31 | -159.16 | -30.94 | -131.77 | -179.2 |
Interest & Investment Income | 847.86 | 493.14 | 508.32 | 555.74 | 493.74 | 79.1 |
Earnings From Equity Investments | -100.5 | -104.79 | -75 | -55.71 | -25.4 | -11.41 |
Other Non Operating Income (Expenses) | -143.94 | 223.56 | 47.74 | -285.74 | -1,346 | 52.82 |
EBT Excluding Unusual Items | 8,685 | 3,332 | -3,825 | -8,381 | -13,353 | -9,198 |
Gain (Loss) on Sale of Investments | -378.48 | -416.4 | -64.98 | -48.74 | -172.69 | 59.63 |
Gain (Loss) on Sale of Assets | 0.75 | - | - | - | - | - |
Other Unusual Items | - | - | - | 2,573 | - | - |
Pretax Income | 8,298 | 2,916 | -3,890 | -5,856 | -13,526 | -9,139 |
Income Tax Expense | 1,457 | 908.72 | 815.93 | 396.18 | 295.05 | 122.15 |
Earnings From Continuing Operations | 6,841 | 2,007 | -4,706 | -6,252 | -13,821 | -9,261 |
Net Income | 6,841 | 2,007 | -4,706 | -6,252 | -13,821 | -9,261 |
Net Income to Common | 6,841 | 2,007 | -4,706 | -6,252 | -13,821 | -9,261 |
Net Income Growth | 1301.83% | - | - | - | - | - |
Shares Outstanding (Basic) | 112 | 109 | 105 | 104 | 103 | 93 |
Shares Outstanding (Diluted) | 117 | 113 | 105 | 104 | 103 | 93 |
Shares Change | 4.74% | 7.75% | 0.86% | 1.22% | 11.15% | 11.16% |
EPS (Basic) | 61.12 | 18.40 | -44.70 | -59.89 | -134.01 | -99.81 |
EPS (Diluted) | 58.30 | 17.28 | -44.70 | -59.92 | -134.01 | -99.81 |
EPS Growth | 1269.44% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 9,950 | 6,587 | -4,622 | -12,192 | -12,567 | -9,921 |
Free Cash Flow Per Share | 85.35 | 58.06 | -43.90 | -116.79 | -121.85 | -106.92 |
Gross Margin | 89.81% | 87.49% | 84.41% | 84.55% | 79.77% | 85.98% |
Operating Margin | 19.60% | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% |
Profit Margin | 15.82% | 5.37% | -16.92% | -35.86% | -141.52% | -123.93% |
Free Cash Flow Margin | 23.01% | 17.63% | -16.62% | -69.93% | -128.68% | -132.76% |
EBITDA | 9,439 | 4,048 | -2,928 | -7,969 | -11,909 | -8,851 |
EBITDA Margin | 21.83% | 10.83% | -10.53% | -45.71% | -121.94% | -118.44% |
D&A For EBITDA | 966.84 | 921.04 | 1,219 | 595.18 | 434.89 | 288.99 |
EBIT | 8,472 | 3,127 | -4,147 | -8,564 | -12,344 | -9,140 |
EBIT Margin | 19.60% | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% |
Effective Tax Rate | 17.55% | 31.17% | - | - | - | - |
Revenue as Reported | 35,840 | 37,371 | 27,811 | 17,435 | 9,766 | 7,472 |